Chaga mushrooms: Traditional Uses, Modern Research and Kidney Safety

What is chaga?

Chaga is Inonotus obliquus, a wood-associated fungus best known for the hard, irregular growth it forms on birch trees. The outside is black and cracked, while the interior is orange-brown and corky. This growth is called a sterile conk: it is different from the fungus's actual spore-producing body, which develops beneath bark after the tree dies. Alaska's botanical profile^[1] describes this distinction and its northern distribution.

The conk is the material traditionally dried and prepared as a drink. Modern products include loose chunks, powder, tea, liquid or dried extracts and mushroom-coffee blends. A drink made by extracting material into water differs from swallowing the whole powder; cultivated fungal material is another preparation whose composition may differ.

Historical uses and modern preparations

Chaga belongs to several northern folk-medicine traditions. A 1991 ethnomycological report^[2] documents its use among the Khanty of West Siberia. Norway's National Research Center in Complementary and Alternative Medicine^[3] describes both general strengthening uses and use for particular illnesses, including gastritis, liver disease, tuberculosis, parasites and cancer. These are records of what people used it for, rather than demonstrated treatment outcomes.

Traditional preparation involved drying and grinding the material to make tea or a decoction, a drink prepared by heating it in water. This helps explain its place as a tonic drink as well as a medicinal ingredient. Today's capsules, concentrated extracts and multi-ingredient coffees introduce different amounts and processing methods. A history of drinking chaga does not specify the exposure from any one modern supplement.

The overlap with modern research is clearest in the questions being asked: immune regulation, inflammation, blood sugar and cancer biology. Researchers now examine particular extracts and compounds in cell or animal experiments, while human safety reports describe actual patterns of use.

Why do people take chaga?

An “antioxidant” label describes a proposed property, not a demonstrated improvement in health. Memorial Sloan Kettering Cancer Center's review^[4] separates laboratory and animal findings from benefits actually demonstrated in people.

Who should be especially cautious?

Reduced urination, new swelling or persistent vomiting warrants prompt medical advice; severe symptoms need urgent care.

Is there a recommended amount?

No effective chaga-alone clinical dose or reliably safe long-term amount was established in the reviewed sources.

Tea, whole powder and extracts create different exposures; no safe conversion between them has been established.

What can a label tell you?

Check the species, whether the product uses the hard tree-associated growth or another cultivated fungal material, its preparation (tea, powder or extract) and full serving amount. “Dual extract” and “wild harvested” do not quantify the product's oxalate content.

Even a laboratory report describing a product's composition cannot supply the missing human benefit evidence or establish a safe oxalate cutoff for you. A coffee blend needs individual ingredient amounts; its total mushroom weight is not its chaga exposure.

The science behind chaga

Antioxidant and immune claims

Some studies involving human material are laboratory experiments rather than supplementation trials. In one study^[5], researchers added chaga extract to isolated blood cells from 20 people with inflammatory bowel disease and 20 healthy volunteers, then exposed the cells to an oxidant. The extract reduced a measure of DNA damage. Participants did not take chaga, so the result does not show what drinking tea or taking capsules does inside the body.

MSK's professional review^[4] also describes preclinical antitumor, glucose-lowering and immune effects. These findings provide reasons for further research; they have not established a chaga treatment for cancer, diabetes or recurrent infections.

What human combination studies can tell us

Chaga has appeared in human trials of mixtures. A 2024 placebo-controlled crossover study in 20 cyclists^[6] tested a beet-based product for two weeks per treatment period, separated by two weeks without either treatment, before a 2.25-hour cycling challenge. The daily product supplied 212 mg nitrate, 200 mg caffeine, vitamin C and B vitamins, plus a mushroom blend containing cordyceps and chaga. The abstract and methods give different blend amounts and ingredient lists. Twenty of the 25 enrolled cyclists completed the study. Blood nitrate and nitrite rose, while a group of proteins involved in inflammation decreased. The study measured blood responses after exercise, not infection rates, and could not isolate chaga’s contribution.

A placebo-controlled crossover study in 20 healthy young men^[7] tested single doses of DTS20, a mixture containing 40% mistletoe, 30% goji, 20% chaga and 10% Acanthopanax. Each 2.5 g dose was mixed into 200 mL water and followed thirty minutes later by 360 mL of a 19% alcohol drink; the treatment periods were separated by one week. Blood alcohol was lower two hours after the mixture than after placebo, but acetaldehyde, a breakdown product of alcohol, did not differ significantly between treatments. The report names 20 participants, while its alcohol-results figure describes 10; that analysis-count discrepancy remains unresolved.

Neither study supplies a chaga-alone dose with proven clinical benefit.

What do the human safety reports show?

Published reports describe oxalate nephropathy: kidney injury associated with oxalate crystals in kidney tissue. In one report^[8], a woman had taken four to five teaspoons of chaga powder daily for six months before severe loss of kidney function requiring dialysis, treatment that filters waste from the blood when the kidneys cannot do enough of that work.

A 2020 report^[9] described a 49-year-old man taking 3 g of powder daily for four years, then 9 g daily for another year. He had no reported history of kidney stones, diabetes, hypertension or vitamin C supplements. A kidney biopsy showed oxalate crystals, and dialysis was still required eighteen months later. The remaining powder contained about 14% oxalate by weight.

A 2022 case^[10] involved 10–15 g of powder daily for three months; the report's abstract also describes 500 mg daily of vitamin C. Vitamin C can contribute to oxalate production, making it harder to attribute the entire injury to chaga alone. This patient recovered kidney function and stopped dialysis after a month, following treatment that also included steroids for a second kidney disorder. Recovery therefore differed from the 2020 case. Together, the reports identify a plausible serious hazard; they cannot tell us how often it occurs among users. Their powder amounts are exposures associated with harm, not a safe dosing range.

Bottom line

Chaga has a documented history as a northern medicinal drink, and laboratory research helps explain the interest in its compounds. Human studies of mixtures have not established a chaga-alone benefit. The strongest practical safety evidence comes from kidney-injury cases involving sustained powder use, with outcomes ranging from recovery to ongoing dialysis.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly